(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Metropolitan Greatness: The 6 Urban areas for Quality Living in 2024 - 21st results from Blue Ghost lunar lander reveal how much we still don't know about the moon
- 3Chemical leak in Oklahoma forces evacuations and leaves many ill
- 4Pick Your #1 Kind Of Bread
- 5When does Spotify Wrapped come out? The music streamer says 'soon.'
- Egypt seeks to calm tourist fears over fallout of Iran war
- Watching ‘Home Alone’ with the kids this holiday season? Brace yourself for '6-7.'
- The pace of hiring just fell to the lowest since 2011, outside of the pandemic
- 'Outrageous and illegal' : UNRWA slams Israel for cutting off its water, comms and electric in Gaza
- Genome study reveals milestone in history of cat domestication
- Vote in favor of the subject that you see as generally captivating and intelligent!
- 6 Hints to Upgrade Your Appeal, In addition to Your Outlook
- Vote in favor of Your Number one kind of pie
- Miley Cyrus flashes a diamond ring on the red carpet, sparking engagement rumors with Maxx Morando: A timeline of their four-year relationship
